Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Peterson, L.

Search results

  • RSS Feed
(1 - 10 of 10)
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
THE EFFECT OF CERTOLIZUMAB PEGOL ON RADIOGRAPHIC PROGRESSION OVER 4 YEARS OF TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-AXSPA TRIAL
CERTOLIZUMAB PEGOL FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-PSA TRIAL
Effect of certolizumab pegol on dermatologic outcomes over 96 weeks in patients with psoriatic arthritis
LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS WITH AND WITHOUT PRIOR ANTI-TUMOR NECROSIS FACTOR EXPOSURE: 96-WEEK OUTCOMES OF THE RAPID-PSA TRIAL
Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
Effect of Certolizumab Pegol Over 48 Weeks on Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure
LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS WITH AND WITHOUT PRIOR ANTI-TUMOR NECROSIS FACTOR EXPOSURE: 96-WEEK OUTCOMES FROM THE RAPID-PSA TRIAL
Effect Of Certolizumab Pegol Over 48 Weeks On Signs and Symptoms In Patients With Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Exposure